Choosing first-generation EGFR-TKIs, such as gefitinib or erlotinib, as the treatment of choice may be reasonable, as there is a lower chance of discontinuation due to drug-induced ILD with these EGFR-TKIs. Here, EGFR is linked to interstitial lung disease.